Increlex is a solution for injection that contains the active substance mecaserminbuy increlex10mg/ml mecasermine online.Increlex is used for the long-term treatment of patients aged two to 18 years who are short for their age due to a condition known as ‘severe primary insulin-like-growth-factor-1 deficiency’. Patients with this condition have low levels of the hormone insulin-like growth factor-1 or IGF-1, which is required for normal growth.buy increlex10mg/ml mecasermine online
Because the number of patients with primary IGF-1 deficiency is low, the disease is considered ‘rare’, and Increlex was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 22 May 2006.
The medicine can only be obtained with a prescription.
IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. The amino acid sequence of the product is identical to that of endogenous human IGF-1.
The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1.buy increlex10mg/ml mecasermine online
INCRELEX® is a sterile, aqueous, clear and colorless solution intended for subcutaneous injection. Each multi-dose vial of INCRELEX® contains 10 mg per mL mecasermin, 9 mg per mL benzyl alcohol, 5.84 mg per mL sodium chloride, 2 mg per mL polysorbate 20, and 0.05M acetate at a pH of approximately 5.4.
Severe Primary IGF-1 Deficiency (Primary IGFD)
INCRELEX is indicated for the treatment of growth failure in children with:
- severe primary IGF-1 deficiency or
- growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
Severe Primary IGF-1 deficiency (IGFD) is defined by:
- height standard deviation score ≤ –3.0 and
- basal IGF-1 standard deviation score ≤ –3.0 and
- normal or elevated growth hormone (GH).
Severe Primary IGFD includes classical and other forms of growth hormone insensitivity. Patients with Primary IGFD may have mutations in the GH receptor (GHR), post-GHR signaling pathway including the IGF-1 gene. They are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment.
INCRELEX is not intended for use in subjects with secondary forms of IGF-1 deficiency, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids. Thyroid and nutritional deficiencies should be corrected before initiating INCRELEX treatment.buy increlex10mg/ml mecasermine online
Limitations of use
INCRELEX is not a substitute to GH for approved GH indications.
The dose of Increlex is individualized by the doctor for each individual’. If a dose is well-tolerated for at least one week, then the doctor may choose to increase the dose by 0.04 mg/kg per dose, to the maximum dose of 0.12 mg/kg given twice daily.*
insulin-like growth factor (IGF-1) increase strength and stimulate muscle growth. … Finally, insulin facilitates the storage of glucose in muscles for future use.In addition to a direct anabolic effect on skeletal muscle—for example, the production of more protein—IGF-I is also capable of stimulating the proliferation and differentiation of muscle stem cells (satellite cells). Results of animal studies suggest that this process is obligatory for muscle hypertrophy to proceedbuy increlex10mg/ml mecasermine online
Available at anti-aging clinics, IGF–1, or insulinlike growth factor-1, has also found favor among athletes for the same reasons that its better-known relative human growth hormone has: it is believed to make an athlete bigger, faster and stronger. It may boost muscle, reduce fat and improve endurance.
The following serious adverse reactions are described below and elsewhere in the labeling: